<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:department>Contracts Office</gtr:department><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1F2CCC33-A16C-432E-B2F2-2AD8828615D3"><gtr:id>1F2CCC33-A16C-432E-B2F2-2AD8828615D3</gtr:id><gtr:firstName>Mervyn</gtr:firstName><gtr:surname>Bibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FJ%2F000CA334"><gtr:id>33659A58-E221-4827-9B6A-0463EA959F04</gtr:id><gtr:title>Developing DNA-based therapies as a new class of treatment for pathogenic bacterial infections</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/J/000CA334</gtr:grantReference><gtr:abstractText>The technology we are developing is a novel way to modify bacterial gene expression in vivo that may lead to the development of powerful therapies to treat infectious diseases. Essentially our approach is to adapt a new class of DNA-based therapeutics - Transcription Factor Decoys (TFDs) - devised originally for treating eukaryotic cells for use against pathogenic bacterial infections, in combination with existing or new antibiotics. The utility of many currently prescribed antibiotics is compromised by the presence of resistance mechanisms in the infectious bacteria, as evidenced by the rise of multi-drug resistant infections in hospitals and increasingly within the community. Our approach is to use TFDs to inactivate these resistance mechanisms by preventing the induction of the genes encoding resistance, many of which are activated in response to antibiotic treatment, and in so doing restore efficacy of the antibiotics. As well as inactivating resistance mechanisms, a parallel approach will be to inhibit growth of pathogenic bacteria by using TFDs to prevent expression of essential genes involved, for example, in the cell cycle or primary metabolism. There are three main project objectives: (1) To demonstrate that TFDs can be used to inactivate antibiotic resistance in a human pathogen (the model used will be vancomycin resistance in Enterococcus faecium). (2) To adapt the approach so TFDs can be deployed to modify gene expression in Gram-negative bacteria such as Escherichia coli. (3) To target genes essential for growth with TFDs to determine whether these are candidates for therapeutic intervention.</gtr:abstractText><gtr:fund><gtr:end>2009-06-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-06-16</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>20632</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/J/000CA334</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>